Pub Date : 2024-07-04eCollection Date: 2024-01-01DOI: 10.5414/ALX02502E
Mustafa Ilker Inan, Yasemin Akgul Balaban, Sait Yesillik, Ozgur Kartal
Introduction: Anaphylaxis is a severe and life-threatening systemic hypersensitivity reaction. The most frequently encountered causes are foods, drugs, and bee venom, but anaphylaxis may also occur idiopathically. Paradoxical vocal cord movement (PVCM), is a cause of upper airway obstruction due to abnormal adduction of vocal cords during inspiration and, to some degree on expiration. It may be misdiagnosed as asthma or anaphylaxis, and there may be delays in diagnosis.
Case report: We present a 20-year-old male patient with coexistence of urticaria and stridor findings who was evaluated and treated as having idiopathic anaphylaxis but then was diagnosed with PVCM after recurrence of stridor attacks.
Conclusion: It is useful to bear the diagnosis of PVCM in mind in patients with recurrent and unexplained stridor or in patients with stridor that does not improve despite treatment for another diagnosis such as anaphylaxis. This way, administration of epinephrine, high-dose corticosteroids and interventions such as intubation or tracheostomy can be avoided.
{"title":"A case of paradoxical vocal cord movement misdiagnosed as anaphylaxis.","authors":"Mustafa Ilker Inan, Yasemin Akgul Balaban, Sait Yesillik, Ozgur Kartal","doi":"10.5414/ALX02502E","DOIUrl":"10.5414/ALX02502E","url":null,"abstract":"<p><strong>Introduction: </strong>Anaphylaxis is a severe and life-threatening systemic hypersensitivity reaction. The most frequently encountered causes are foods, drugs, and bee venom, but anaphylaxis may also occur idiopathically. Paradoxical vocal cord movement (PVCM), is a cause of upper airway obstruction due to abnormal adduction of vocal cords during inspiration and, to some degree on expiration. It may be misdiagnosed as asthma or anaphylaxis, and there may be delays in diagnosis.</p><p><strong>Case report: </strong>We present a 20-year-old male patient with coexistence of urticaria and stridor findings who was evaluated and treated as having idiopathic anaphylaxis but then was diagnosed with PVCM after recurrence of stridor attacks.</p><p><strong>Conclusion: </strong>It is useful to bear the diagnosis of PVCM in mind in patients with recurrent and unexplained stridor or in patients with stridor that does not improve despite treatment for another diagnosis such as anaphylaxis. This way, administration of epinephrine, high-dose corticosteroids and interventions such as intubation or tracheostomy can be avoided.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"233-237"},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-25eCollection Date: 2024-01-01DOI: 10.5414/ALX400582
Jozélio Freire de Carvalho
Objective: To describe a young patient with scorpion sting (SS) with typical lesions of urticaria besides the local SS clinical picture.
Materials and methods: A systematic screening of articles dating from 1966 to 2021 was conducted in the main databases. All articles included the association between SS and urticaria. A new case report is added to the published list.
Results: The literature search found 5 articles with 29 patients with SS and urticaria/allergic reactions. We performed our analysis by adding our present case, resulting in a total of 30 cases. Most were male, and their ages varied from 29 to 48 years. Regarding SS severity, most were mild or moderate. In two articles, patients had more than one sting. The allergic reaction varied from urticaria, pruritus, flushing, angioedema, wheezing, rhinorrhea, sneezing, consciousness alterations, and gastrointestinal and cardiovascular alterations. In 5/6 (83%) articles, the patients were alive at the study time. One subject died from anaphylactic shock.
Conclusion: The present article systematically reviewed all published cases of SS and allergic reactions to scorpion venom. It is an infrequent association; most patients are male and in the productive age, and reaction may vary from mild to severe, including death.
摘要描述一名年轻的蝎子蜇伤(SS)患者,除了蝎子蜇伤的局部临床表现外,还伴有典型的荨麻疹皮损:在主要数据库中对 1966 年至 2021 年的文章进行了系统筛选。所有文章均包含 SS 与荨麻疹之间的关联。结果:文献检索共发现 5 篇文章,涉及 29 名 SS 和荨麻疹/过敏反应患者。我们在进行分析时加入了本病例,结果共有 30 例。大多数患者为男性,年龄从 29 岁到 48 岁不等。关于 SS 的严重程度,大多数为轻度或中度。在两篇文章中,患者被蛰了不止一次。过敏反应包括荨麻疹、瘙痒、潮红、血管性水肿、喘息、鼻出血、打喷嚏、意识改变、胃肠道和心血管改变。在5/6(83%)篇文章中,患者在研究期间仍然存活。一名患者死于过敏性休克:本文系统回顾了所有已发表的SS和蝎毒过敏反应病例。蝎毒过敏症是一种不常见的疾病,大多数患者为男性,处于生育年龄,反应从轻微到严重不等,包括死亡。
{"title":"Scorpion sting and allergic reaction to scorpion venom: A case-based review.","authors":"Jozélio Freire de Carvalho","doi":"10.5414/ALX400582","DOIUrl":"10.5414/ALX400582","url":null,"abstract":"<p><strong>Objective: </strong>To describe a young patient with scorpion sting (SS) with typical lesions of urticaria besides the local SS clinical picture.</p><p><strong>Materials and methods: </strong>A systematic screening of articles dating from 1966 to 2021 was conducted in the main databases. All articles included the association between SS and urticaria. A new case report is added to the published list.</p><p><strong>Results: </strong>The literature search found 5 articles with 29 patients with SS and urticaria/allergic reactions. We performed our analysis by adding our present case, resulting in a total of 30 cases. Most were male, and their ages varied from 29 to 48 years. Regarding SS severity, most were mild or moderate. In two articles, patients had more than one sting. The allergic reaction varied from urticaria, pruritus, flushing, angioedema, wheezing, rhinorrhea, sneezing, consciousness alterations, and gastrointestinal and cardiovascular alterations. In 5/6 (83%) articles, the patients were alive at the study time. One subject died from anaphylactic shock.</p><p><strong>Conclusion: </strong>The present article systematically reviewed all published cases of SS and allergic reactions to scorpion venom. It is an infrequent association; most patients are male and in the productive age, and reaction may vary from mild to severe, including death.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"229-232"},"PeriodicalIF":0.0,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-13eCollection Date: 2024-01-01DOI: 10.5414/ALX02400ECorr
[This corrects the article on p. 57 in vol. 7, PMID: 37056444.].
[此处更正了第 7 卷第 57 页的文章,PMID:37056444]。
{"title":"Corrigendum of the article Reese I, Schäfer C, Ballmer-Weber B, Beyer K, Dölle-Bierke S, van Dullemen S, Jappe U, Müller S, Schnadt S, Treudler R, Worm M. Vegan diets from an allergy point of view - Position paper of the DGAKI working group on food allergy. Allergol Select. 2023; 7: 57-83.","authors":"","doi":"10.5414/ALX02400ECorr","DOIUrl":"https://doi.org/10.5414/ALX02400ECorr","url":null,"abstract":"<p><p>[This corrects the article on p. 57 in vol. 7, PMID: 37056444.].</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"228"},"PeriodicalIF":0.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11170463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-31eCollection Date: 2024-01-01DOI: 10.5414/ALX02480E
Irena Neustädter, Sophie Blatt, Gerda Wurpts, Heinrich Dickel, Christian Walter, Werner Aberer, Sebastian Bode, Timo Buhl, Sunhild Gernert, Susanne Harner, Guido Heine, Sebastian Kerzel, Meike Köhler, Lars Lange, Joachim List, Hans F Merk, Thomas Nüßlein, Hagen Ott, Franziska Sattler, Antje Schuster, Helen Straube, Bettina Wedi, Torsten Zuberbier, Knut Brockow
Background: Approximately 10% of European children are classified as allergic to drugs. In the majority of these children, no allergy to β-lactam antibiotics (BLA) can be found. In most cases, the exanthema is caused by the infection.
Materials and methods: The objective of this paper is to describe the causes and consequences of a misdiagnosis of drug allergy. We propose a method for establishing a correct diagnosis in the case of a history of a delayed reaction during treatment with a BLA. For this purpose, a proposal was discussed via e-mail communication, and consensus was reached among the members of the drug allergy working groups of the participating medical societies.
Results: The suspicion of a BLA allergy based on the medical history alone can have a negative impact on future antibiotic treatment. Exanthema associated with febrile infections not related to drug administration is a frequent finding in children. This makes it all the more important to be able to recommend a standardized procedure for clarification in children and adolescents with suspected hypersensitivity reactions. The medical history should be the basis on which to diagnose either a drug allergy or another possible differential diagnosis. A mild maculopapular exanthema (MPE) can be an expression of a drug allergy or a nonspecific viral exanthema. Uncomplicated MPE is not associated with significant systemic involvement, and there is no involvement of the mucous membranes or cutaneous blistering. Only a small number of children with uncomplicated MPE show positive skin tests and only ~ 7 - 16% of suspected BLA diagnoses can be confirmed by provocation tests. Thus, in children with uncomplicated MPE, drug provocation can be performed in an outpatient setting even without prior skin testing. This paper presents a 3-day outpatient direct provocation scheme for BLA delabeling in children with uncomplicated MPE.
Conclusion: Many children and adolescents are unnecessarily denied treatment with BLA after an uncomplicated MPE while being treated with a BLA.
背景:约有 10% 的欧洲儿童被归类为对药物过敏。在这些儿童中,大多数都没有发现对β-内酰胺类抗生素(BLA)过敏。在大多数情况下,红斑是由感染引起的:本文旨在描述药物过敏误诊的原因和后果。我们提出了一种在使用 BLA 治疗期间出现延迟反应病史的情况下确定正确诊断的方法。为此,我们通过电子邮件交流的方式讨论了这一建议,并在参与医学会的药物过敏工作组成员之间达成了共识:结果:仅凭病史怀疑对 BLA 过敏会对今后的抗生素治疗产生负面影响。与用药无关的发热感染引起的红斑是儿童的常见病。因此,为疑似超敏反应的儿童和青少年推荐一个标准化的澄清程序就显得尤为重要。病史应作为诊断药物过敏或其他可能鉴别诊断的依据。轻度斑丘疹性红斑(MPE)可能是药物过敏或非特异性病毒性红斑的表现。无并发症的 MPE 不伴有明显的全身受累,也没有粘膜受累或皮肤水疱。只有少数无并发症的 MPE 患儿的皮肤测试呈阳性,只有 ~ 7 - 16% 的疑似 BLA 诊断可通过激发试验得到证实。因此,对于无并发症的 MPE 患儿,即使事先未进行皮试,也可在门诊环境中进行药物激发试验。本文介绍了一种为期 3 天的门诊直接激发方案,用于对无并发症的 MPE 儿童进行 BLA 脱标:结论:许多儿童和青少年在发生无并发症的 MPE 后,在接受 BLA 治疗的同时却被不必要地拒绝接受 BLA 治疗。
{"title":"\"Delabeling\" by direct provocation testing in children and adolescents with a suspected history of a delayed reaction to β-lactam antibiotics: Consensus paper of Gesellschaft für pädiatrische Allergologie und Umweltmedizin (GPAU), Deutsche Gesellschaft für Allergologie und klinische Immunologie (DGAKI), and Ärzteverband deutscher Allergologen (ÄDA).","authors":"Irena Neustädter, Sophie Blatt, Gerda Wurpts, Heinrich Dickel, Christian Walter, Werner Aberer, Sebastian Bode, Timo Buhl, Sunhild Gernert, Susanne Harner, Guido Heine, Sebastian Kerzel, Meike Köhler, Lars Lange, Joachim List, Hans F Merk, Thomas Nüßlein, Hagen Ott, Franziska Sattler, Antje Schuster, Helen Straube, Bettina Wedi, Torsten Zuberbier, Knut Brockow","doi":"10.5414/ALX02480E","DOIUrl":"10.5414/ALX02480E","url":null,"abstract":"<p><strong>Background: </strong>Approximately 10% of European children are classified as allergic to drugs. In the majority of these children, no allergy to β-lactam antibiotics (BLA) can be found. In most cases, the exanthema is caused by the infection.</p><p><strong>Materials and methods: </strong>The objective of this paper is to describe the causes and consequences of a misdiagnosis of drug allergy. We propose a method for establishing a correct diagnosis in the case of a history of a delayed reaction during treatment with a BLA. For this purpose, a proposal was discussed via e-mail communication, and consensus was reached among the members of the drug allergy working groups of the participating medical societies.</p><p><strong>Results: </strong>The suspicion of a BLA allergy based on the medical history alone can have a negative impact on future antibiotic treatment. Exanthema associated with febrile infections not related to drug administration is a frequent finding in children. This makes it all the more important to be able to recommend a standardized procedure for clarification in children and adolescents with suspected hypersensitivity reactions. The medical history should be the basis on which to diagnose either a drug allergy or another possible differential diagnosis. A mild maculopapular exanthema (MPE) can be an expression of a drug allergy or a nonspecific viral exanthema. Uncomplicated MPE is not associated with significant systemic involvement, and there is no involvement of the mucous membranes or cutaneous blistering. Only a small number of children with uncomplicated MPE show positive skin tests and only ~ 7 - 16% of suspected BLA diagnoses can be confirmed by provocation tests. Thus, in children with uncomplicated MPE, drug provocation can be performed in an outpatient setting even without prior skin testing. This paper presents a 3-day outpatient direct provocation scheme for BLA delabeling in children with uncomplicated MPE.</p><p><strong>Conclusion: </strong>Many children and adolescents are unnecessarily denied treatment with BLA after an uncomplicated MPE while being treated with a BLA.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"206-211"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-31eCollection Date: 2024-01-01DOI: 10.5414/ALX02505E
Julia Zimmer, Vera Mahler
Development, production, and marketing authorization of allergen products is generally challenging due to several specific characteristics, including the natural source as well as the multitude of allergenic materials. Also, depending on the frequency of sensitization in the population, the number of patients available for inclusion in clinical trials can be a limiting factor for product development. In the development of allergen products for diagnosis of type I and type IV allergies these challenges are particularly demanding because, in contrast to certain products for allergen-specific immunotherapy, no exemptions from marketing authorization are foreseen for this product group in Directive 2001/83/EC. Thus, the regulatory framework is constantly adapted within the legal scope in order to balance necessary regulatory requirements ensuring quality, safety, and efficacy with the clinical need for a comprehensive range of diagnostic allergen products. In this article, we give an overview on the current regulatory framework for development and marketing authorization of allergen products for diagnosis of rare type I and type IV allergies.
过敏原产品的开发、生产和市场授权一般都具有挑战性,这是因为过敏原产品具有几个特定的特征,包括天然来源和多种过敏原材料。此外,根据人群中过敏发生的频率,可纳入临床试验的患者人数也可能成为产品开发的限制因素。在开发用于诊断 I 型和 IV 型过敏症的过敏原产品时,这些挑战尤为严峻,因为与某些用于过敏原特异性免疫疗法的产品不同,2001/83/EC 号指令并没有为这类产品规定上市许可豁免。因此,监管框架需要在法律范围内不断调整,以便在确保质量、安全性和有效性的必要监管要求与临床对全面诊断过敏原产品的需求之间取得平衡。在本文中,我们将概述目前用于诊断罕见的 I 型和 IV 型过敏症的过敏原产品的开发和上市许可的监管框架。
{"title":"Regulatory framework for development and marketing authorization of allergen products for diagnosis of rare type I and type IV allergies: The current status.","authors":"Julia Zimmer, Vera Mahler","doi":"10.5414/ALX02505E","DOIUrl":"10.5414/ALX02505E","url":null,"abstract":"<p><p>Development, production, and marketing authorization of allergen products is generally challenging due to several specific characteristics, including the natural source as well as the multitude of allergenic materials. Also, depending on the frequency of sensitization in the population, the number of patients available for inclusion in clinical trials can be a limiting factor for product development. In the development of allergen products for diagnosis of type I and type IV allergies these challenges are particularly demanding because, in contrast to certain products for allergen-specific immunotherapy, no exemptions from marketing authorization are foreseen for this product group in Directive 2001/83/EC. Thus, the regulatory framework is constantly adapted within the legal scope in order to balance necessary regulatory requirements ensuring quality, safety, and efficacy with the clinical need for a comprehensive range of diagnostic allergen products. In this article, we give an overview on the current regulatory framework for development and marketing authorization of allergen products for diagnosis of rare type I and type IV allergies.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"212-219"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-31eCollection Date: 2024-01-01DOI: 10.5414/ALX02500E
Monika Raulf, Sabine Kespohl
Occupational skin and respiratory allergies are among the most common occupational diseases in Germany. The identification of the allergy trigger is essential for the recognition of an occupational allergy as well as for effective individual prevention. However, occupational type I allergens are among the "rare" allergens and the possibilities of guideline-compliant diagnosis using quality-tested skin test solutions is becoming increasingly difficult due to the reduction in commercially available test allergens. In order to guarantee meaningful diagnostic workup for all affected insured persons with suspected occupational type I allergies and to ensure this in the future, a durable optimization, standardization, and availability of allergy tests for occupational allergic diseases is urgently required. The need for action has been recognized by the German Social Accident Insurance (DGUV), and steps to eliminate the diagnostic gaps have been initiated by a joint research project at the Institute for Prevention and Occupational Medicine of the DGUV (IPA) and the Paul Ehrlich Institut (PEI). The evaluation of alternative methods for the production of standardized test allergen solutions can also be used for newly emerging allergens in the workplace. New allergen sources at workplaces and thus also sensitization and allergies among employees can be expected as a result of changes in work processes and the introduction of new technologies and/or working materials, which are also introduced in connection with climate change and the concept of sustainability.
在德国,职业性皮肤和呼吸道过敏是最常见的职业病之一。过敏诱因的识别对于识别职业过敏症和有效预防个人过敏症至关重要。然而,职业 I 型过敏原属于 "罕见 "过敏原,而且由于市售过敏原检测试剂的减少,使用经过质量检测的皮试方案进行符合指南要求的诊断变得越来越困难。为了保证对所有疑似 I 型职业性过敏的受影响投保人进行有意义的诊断工作,并在未来确保这一点,迫切需要对职业性过敏性疾病的过敏试验进行持久的优化、标准化和可用性。德国社会事故保险局(DGUV)已认识到这一行动的必要性,并已通过德国社会事故保险局预防与职业医学研究所(IPA)和保罗-埃利希研究所(PEI)的一个联合研究项目启动了消除诊断差距的措施。对生产标准化测试过敏原溶液的替代方法进行评估,也可用于工作场所新出现的过敏原。由于工作流程的改变以及新技术和/或工作材料的引入,工作场所可能会出现新的过敏源,从而导致员工过敏。
{"title":"Diagnostics of IgE-mediated occupational allergies: Between reality, requirements, and opportunities.","authors":"Monika Raulf, Sabine Kespohl","doi":"10.5414/ALX02500E","DOIUrl":"10.5414/ALX02500E","url":null,"abstract":"<p><p>Occupational skin and respiratory allergies are among the most common occupational diseases in Germany. The identification of the allergy trigger is essential for the recognition of an occupational allergy as well as for effective individual prevention. However, occupational type I allergens are among the \"rare\" allergens and the possibilities of guideline-compliant diagnosis using quality-tested skin test solutions is becoming increasingly difficult due to the reduction in commercially available test allergens. In order to guarantee meaningful diagnostic workup for all affected insured persons with suspected occupational type I allergies and to ensure this in the future, a durable optimization, standardization, and availability of allergy tests for occupational allergic diseases is urgently required. The need for action has been recognized by the German Social Accident Insurance (DGUV), and steps to eliminate the diagnostic gaps have been initiated by a joint research project at the Institute for Prevention and Occupational Medicine of the DGUV (IPA) and the Paul Ehrlich Institut (PEI). The evaluation of alternative methods for the production of standardized test allergen solutions can also be used for newly emerging allergens in the workplace. New allergen sources at workplaces and thus also sensitization and allergies among employees can be expected as a result of changes in work processes and the introduction of new technologies and/or working materials, which are also introduced in connection with climate change and the concept of sustainability.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"220-227"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03eCollection Date: 2024-01-01DOI: 10.5414/ALX02471E
Imke Reese
Since the EAT-Lancet Commission's call for a change in diet towards more plant-based foods, especially protein sources, this so called "Planetary Health Diet (PHD)" has been widely discussed. While for some the reduction in animal foods is not enough and vegan diets are advocated to save the climate, others are sounding the alarm that the reduction is too drastic and that the PHD makes it impossible to provide a diet that meets our needs (of essential nutrients). In addition to climate aspects, health benefits often cited to justify the PHD do not take into account that vegetarians/vegans differ from the general population by far more factors than the reduction or elimination of animal foods. Also not sufficiently discussed is the fact that a diet which excludes or severely restricts animal foods is also associated with health risks if critical nutrients are not adequately covered. Moreover, the challenge of meeting protein requirements is underestimated by many. The food industry has responded to the trend towards more plant-based foods by massively expanding the range of highly processed or ultra-processed vegan foods. These - vegan or not vegan - are suspected of being partly responsible for the development of non-communicable diseases. In addition to general criticism regarding the usefulness of advertising the PHD, the replacement of animal protein sources with plant-based sources notably harbors a number of additional relevant risks for allergy sufferers so that the latter should be classified as an unfavorable target group for the implementation of the PHD recommendations.
{"title":"\"Climate-friendly\" diets from an allergy point of view.","authors":"Imke Reese","doi":"10.5414/ALX02471E","DOIUrl":"https://doi.org/10.5414/ALX02471E","url":null,"abstract":"<p><p>Since the EAT-Lancet Commission's call for a change in diet towards more plant-based foods, especially protein sources, this so called \"Planetary Health Diet (PHD)\" has been widely discussed. While for some the reduction in animal foods is not enough and vegan diets are advocated to save the climate, others are sounding the alarm that the reduction is too drastic and that the PHD makes it impossible to provide a diet that meets our needs (of essential nutrients). In addition to climate aspects, health benefits often cited to justify the PHD do not take into account that vegetarians/vegans differ from the general population by far more factors than the reduction or elimination of animal foods. Also not sufficiently discussed is the fact that a diet which excludes or severely restricts animal foods is also associated with health risks if critical nutrients are not adequately covered. Moreover, the challenge of meeting protein requirements is underestimated by many. The food industry has responded to the trend towards more plant-based foods by massively expanding the range of highly processed or ultra-processed vegan foods. These - vegan or not vegan - are suspected of being partly responsible for the development of non-communicable diseases. In addition to general criticism regarding the usefulness of advertising the PHD, the replacement of animal protein sources with plant-based sources notably harbors a number of additional relevant risks for allergy sufferers so that the latter should be classified as an unfavorable target group for the implementation of the PHD recommendations.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"199-205"},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03eCollection Date: 2024-01-01DOI: 10.5414/ALX2483E
Richard Brans, Christoph Skudlik
Allergic contact dermatitis is one of the most frequent occupational skin diseases. Targeted allergen avoidance can only be achieved by identification of the causative allergen. Therefore, patch testing is of utmost importance in occupational dermatology, not only in terms of assessing causal relationships but also regarding the implementation of prevention measures and evaluation of the legal criteria for an occupational skin disease in Germany (statutory occupational disease BK 5101). The lack of commercial patch test preparations poses a great diagnostic challenge. Patch testing of patient's own materials from their workplace is therefore very important to reduce diagnostic gaps. The performance and documentation of the patch test should be in line with current guidelines and recommendations to ensure the necessary test quality and comprehensibility of the test results.
过敏性接触性皮炎是最常见的职业性皮肤病之一。只有查明致病过敏原,才能有针对性地避免接触过敏原。因此,斑贴试验在职业皮肤病学中至关重要,它不仅能评估因果关系,还能实施预防措施和评估德国职业皮肤病的法定标准(法定职业病 BK 5101)。商业性斑贴试验制剂的缺乏给诊断带来了巨大挑战。因此,对患者自己的工作场所材料进行斑贴试验对于减少诊断差距非常重要。斑贴试验的执行和记录应符合当前的指导方针和建议,以确保必要的试验质量和试验结果的可理解性。
{"title":"Patch testing in occupational dermatology: Practical aspects in relation to the conditions in Germany.","authors":"Richard Brans, Christoph Skudlik","doi":"10.5414/ALX2483E","DOIUrl":"https://doi.org/10.5414/ALX2483E","url":null,"abstract":"<p><p>Allergic contact dermatitis is one of the most frequent occupational skin diseases. Targeted allergen avoidance can only be achieved by identification of the causative allergen. Therefore, patch testing is of utmost importance in occupational dermatology, not only in terms of assessing causal relationships but also regarding the implementation of prevention measures and evaluation of the legal criteria for an occupational skin disease in Germany (statutory occupational disease BK 5101). The lack of commercial patch test preparations poses a great diagnostic challenge. Patch testing of patient's own materials from their workplace is therefore very important to reduce diagnostic gaps. The performance and documentation of the patch test should be in line with current guidelines and recommendations to ensure the necessary test quality and comprehensibility of the test results.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"82-89"},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03eCollection Date: 2024-01-01DOI: 10.5414/ALX02444E
Julia Hurraß, Birger Heinzow, Sandra Walser-Reichenbach, Ute Aurbach, Sven Becker, Romuald Bellmann, Karl-Christian Bergmann, Oliver A Cornely, Steffen Engelhart, Guido Fischer, Thomas Gabrio, Caroline E W Herr, Marcus Joest, Christian Karagiannidis, Ludger Klimek, Martin Köberle, Annette Kolk, Herbert Lichtnecker, Thomas Lob-Corzilius, Norbert Mülleneisen, Dennis Nowak, Uta Rabe, Monika Raulf, Jörg Steinmann, Jens-Oliver Steiß, Jannik Stemler, Ulli Umpfenbach, Kerttu Valtanen, Barbora Werchan, Birgit Willinger, Gerhard A Wiesmüller
None.
无。
{"title":"AWMF mold guideline \"Medical clinical diagnostics for indoor mold exposure\" - Update 2023 AWMF Register No. 161/001.","authors":"Julia Hurraß, Birger Heinzow, Sandra Walser-Reichenbach, Ute Aurbach, Sven Becker, Romuald Bellmann, Karl-Christian Bergmann, Oliver A Cornely, Steffen Engelhart, Guido Fischer, Thomas Gabrio, Caroline E W Herr, Marcus Joest, Christian Karagiannidis, Ludger Klimek, Martin Köberle, Annette Kolk, Herbert Lichtnecker, Thomas Lob-Corzilius, Norbert Mülleneisen, Dennis Nowak, Uta Rabe, Monika Raulf, Jörg Steinmann, Jens-Oliver Steiß, Jannik Stemler, Ulli Umpfenbach, Kerttu Valtanen, Barbora Werchan, Birgit Willinger, Gerhard A Wiesmüller","doi":"10.5414/ALX02444E","DOIUrl":"10.5414/ALX02444E","url":null,"abstract":"<p><p>None.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"90-198"},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-05eCollection Date: 2024-01-01DOI: 10.5414/ALX02485E
Benjamin Klein, Regina Treudler
Background: Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus that belongs to the spectrum of Th2-mediated diseases. It is often associated with atopic comorbidities such as allergic asthma (AA) and poses a therapeutic challenge.
Case report: We report on a 43-year-old patient with EoE and AA who did not show sufficient therapeutic control despite standard therapy. We started treatment with dupilumab, whereupon both EoE and AA rapidly improved and complete symptom resolution could be documented. The response to dupilumab was assessed by laboratory monitoring and gastroscopy, which showed a reduction of markers of type II inflammation and eosinophilic infiltrates in the esophagus.
Summary: Our report emphasizes the effective and safe use of dupilumab as a treatment option for EoE with concomitant beneficial effects on AA.
背景:嗜酸性粒细胞食管炎(EoE)是一种食管炎症性疾病,属于Th2介导的疾病谱。它通常与过敏性哮喘(AA)等特异性合并症相关,给治疗带来了挑战:我们报告了一名 43 岁的咽喉炎和 AA 患者,尽管接受了标准治疗,但病情仍未得到充分控制。我们开始使用杜比鲁单抗治疗,患者的咽喉炎和过敏性哮喘很快得到了改善,症状完全消失。我们通过实验室监测和胃镜检查评估了患者对杜比鲁单抗的反应,结果显示 II 型炎症标志物和食管中的嗜酸性粒细胞浸润均有所减少。摘要:我们的报告强调了杜比鲁单抗作为治疗呃逆的一种有效而安全的选择,同时对 AA 也有好处。
{"title":"Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma.","authors":"Benjamin Klein, Regina Treudler","doi":"10.5414/ALX02485E","DOIUrl":"https://doi.org/10.5414/ALX02485E","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus that belongs to the spectrum of Th2-mediated diseases. It is often associated with atopic comorbidities such as allergic asthma (AA) and poses a therapeutic challenge.</p><p><strong>Case report: </strong>We report on a 43-year-old patient with EoE and AA who did not show sufficient therapeutic control despite standard therapy. We started treatment with dupilumab, whereupon both EoE and AA rapidly improved and complete symptom resolution could be documented. The response to dupilumab was assessed by laboratory monitoring and gastroscopy, which showed a reduction of markers of type II inflammation and eosinophilic infiltrates in the esophagus.</p><p><strong>Summary: </strong>Our report emphasizes the effective and safe use of dupilumab as a treatment option for EoE with concomitant beneficial effects on AA.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"78-81"},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}